Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Related to this article
FDA approves belzutifan plus lenvatinib for advanced clear cell RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Q4 2026 Oncology Outlook: Key FDA Decisions to Watch
2
Historical Outcomes with Cetuximab and Taxanes
3
Tab-Cel BLA Resubmitted to FDA for EBV-Positive PTLD
4
Zabilugene Almadenorepvec Plus Chemo Shows Survival Gains in Metastatic PDAC
5